Ren L, Clawson G A
Department of Pathology, The Pennsylvania State University School of Medicine, Hershey 17033, USA.
Exp Cell Res. 1997 Jul 10;234(1):105-14. doi: 10.1006/excr.1997.3600.
Subunit rLMP7 of the multicatalytic proteinase (MCP), which has been associated with chymotrypsin-like proteinase activity, was examined in rat liver and hepatocyte-derived cell lines. rLMP7 was detected in both nucleus and cytosol in liver by immunohistochemistry and immunoblotting, using a peptide-specific anti-rLMP7 antibody. A M(r) 30,000 precursor protein was present only in cytosol, as was a minor component of M(r) 25,000. Mature rLMP7 (M(r) 23,000) was present in MCP in both nucleus and cytosol, although it was not detectable in the nuclear scaffold. Two rLMP7 cDNAs (designated rLMP7.1 and rLMP7.s) were identified by rapid amplification of 5' ends using RT/PCR, a result which was confirmed by Northern blot analysis and RNase protection assays. rLMP7.1 is 3-4x more abundant than rLMP7.s; it is 50 nt longer than the previously reported cDNA sequence and includes an upstream in-frame ATG within a consensus translation initiation sequence, which encodes the M(r) 30,000 rLMP7 precursor protein identified in vivo. rLMP7.s is 100 nt shorter than rLMP7.1 and does not contain the most 5' ATG. Transient transfection analyses with rLMP7.1 and rLMP7.s constructs coupled to green fluorescent protein showed that both transcripts were efficiently expressed in vivo. In vitro expression of these two rLMP7 cDNAs showed that rLMP7.1 produces the M(r) 30,000 precursor protein, whereas rLMP7.s produces two smaller peptides of M(r) 25,000 and 23,000. Purified 20S MCP preparations were able to proteolytically process the M(r) 30,000 precursor to the M(r) 25,000 product but not to the mature rLMP7 form. However, incorporation of this processed M(r) 25,000 product (or of either M(r) form produced from rLMP7.s) did not occur in vitro. In vitro processing and pulse-chase experiments suggested that the mature M(r) 23,000 subunit is derived, at least in part, from the M(r) 30,000 precursor. The M(r) 25,000 form may be a stable product produced directly from rLMP7.s.
多催化蛋白酶(MCP)的亚基rLMP7与胰凝乳蛋白酶样蛋白酶活性相关,本研究在大鼠肝脏和肝细胞衍生的细胞系中对其进行了检测。使用肽特异性抗rLMP7抗体,通过免疫组织化学和免疫印迹法在肝脏的细胞核和细胞质中均检测到了rLMP7。分子量为30,000的前体蛋白仅存在于细胞质中,还有一个分子量为25,000的次要成分也是如此。成熟的rLMP7(分子量23,000)存在于细胞核和细胞质中的MCP中,尽管在核支架中未检测到。通过RT/PCR快速扩增5'端鉴定出两个rLMP7 cDNA(分别命名为rLMP7.1和rLMP7.s),Northern印迹分析和核糖核酸酶保护试验证实了这一结果。rLMP7.1的丰度比rLMP7.s高3 - 4倍;它比先前报道的cDNA序列长50 nt,并且在共有翻译起始序列内包含一个上游读框内的ATG,该ATG编码在体内鉴定出的分子量为30,000的rLMP7前体蛋白。rLMP7.s比rLMP7.1短100 nt,并且不包含最5'端的ATG。将rLMP7.1和rLMP7.s构建体与绿色荧光蛋白偶联进行瞬时转染分析表明,这两种转录本在体内均能有效表达。这两个rLMP7 cDNA的体外表达表明,rLMP7.1产生分子量为30,000的前体蛋白,而rLMP7.s产生分子量为25,000和23,000的两种较小的肽。纯化的20S MCP制剂能够将分子量为30,000的前体蛋白蛋白酶解加工为分子量为25,000的产物,但不能加工为成熟的rLMP7形式。然而,体外未发生这种加工后的分子量为25,000的产物(或rLMP7.s产生的任何一种分子量形式)的掺入。体外加工和脉冲追踪实验表明,成熟的分子量为23,000的亚基至少部分源自分子量为30,000的前体。分子量为25,000的形式可能是直接由rLMP7.s产生的稳定产物。